Carevive Blog

In The News

Cancer Survivor Population Expected to Reach 22.1 Million by 2030

One in sixteen people in the U.S. will be a cancer survivor by 2030, according to a new report by the American Cancer Society and the National Cancer Institute. The Cancer treatment and survivorship statistics, 2019 report, states that the numbers will soar from 16.9 million Americans with a history of cancer as of the 1st of January this year…
Carevive
June 20, 2019
Events

Carevive to Present Two Posters at the 2019 MASCC/ISOO Annual Meeting

Carevive's Director of Research, Debra Wujcik, PhD, RN, FAAN, will be presenting two posters at the 2019 MASCC/ISOO Annual Meeting in San Francisco on June 21-23.  The posters explore the usage of Carevie's patient-reported outcomes (PROs) tools to assess cancer pain associated with severe flares and end-of-dose failure and how chronic lymphocytic leukemia (CLL) patients can benefit from the collection…
Carevive
June 20, 2019
CME

Multiple Myeloma in 2019: Maintenance Therapy & Treatment Side Effect Management

Release Date: 6/7/2019 Expiration Date: 6/6/2020 Physicians – Maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses – 0.6 contact hours (0.3 pharmacotherapy) Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, hematology/oncology NPs/PAs, and registered nurses. Faculty Rafael Fonseca, MD, FACP Mayo Clinic – Arizona Beth Faiman, PhD, APRN-BC, AOCN Cleveland Clinic Educational Objectives After completing this activity, the participant should be…
Carevive
June 18, 2019
CME

Multiple Myeloma in 2019: Updates and Clinical Trial Data

Release Date: 6/7/2019 Expiration Date: 6/6/2020 Physicians – Maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses – 0.6 contact hours (0.3 pharmacotherapy) Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, hematology/oncology NPs/PAs, and registered nurses. Faculty Rafael Fonseca, MD, FACP Mayo Clinic – Arizona Educational Objectives After completing this activity, the participant should be better able to: Consider clinical trial data…
Carevive
June 18, 2019
CME

Multiple Myeloma in 2019: The Geriatric Assessment Tool and Clinical Evidence

Release Date: 6/7/2019 Expiration Date: 6/6/2020 Physicians – Maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses – 0.5 contact hours Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, hematology/oncology NPs/PAs, and registered nurses. Faculty Tanya Wildes, MD, MSCI Washington University School of Medicine Educational Objectives After completing this activity, the participant should be better able to: Consider real-world evidence when managing…
Carevive
June 7, 2019
CME

Clinically Integrating Patient-Reported Outcomes into Metastatic Colorectal Care Management

Release date: May 22, 2019 
Expiration date: May 21, 2020 Physicians – Maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses – 0.5 contact hours (0.2 pharmacotherapy) Target Audience The target audience for this activity a U.S.-based medical oncologists, oncology Advanced Practice Providers, oncology nurses and nurse navigators. Educational Objectives After completing this activity, the participant should be better able…
Carevive
May 30, 2019
CME

Applying a Shared Decision-Making Framework for Treatment Planning in DLBCL and FL

Release date: May 22, 2019 
Expiration date: May 21, 2020 Physicians – Maximum of 1.0 AMA PRA Category 1 Credits™ Registered Nurses – 1.0 contact hours (0.7 pharmacotherapy) Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, advanced practice nurses, physician assistants, oncology nurses, nurse navigators, and cancer center administrators caring for patients with non-Hodgkin lymphoma. Educational Objectives After completing…
Carevive
May 22, 2019
CME

Evolving Evidence-Based Treatment Paradigms for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Release date: April 15, 2019 
Expiration date: April 14, 2020 Estimated time to complete activity: 45 minutes In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society , 2018). The majority…
Carevive
April 15, 2019
Press Releases

Ethan Basch to Lead Carevive’s Scientific Advisory Board

Patient-reported outcomes research pioneer, Ethan Basch, MD, MSc, FASCO will serve as Scientific Advisory Board Director to build health care technology company’s patient-reported outcomes (PRO) and RWE analytics platform. North Miami, Florida — February 26, 2019 — Carevive, a health technology company that builds cancer care management and patient engagement solutions to improve patient quality of life and clinical outcomes, announced…
Carevive
February 26, 2019